184 related articles for article (PubMed ID: 32797244)
1. Prevalence and clinical correlates of substance use disorders in South African Xhosa patients with schizophrenia.
Temmingh H; Susser E; Mall S; Campbell M; Sibeko G; Stein DJ
Soc Psychiatry Psychiatr Epidemiol; 2021 Apr; 56(4):695-706. PubMed ID: 32797244
[TBL] [Abstract][Full Text] [Related]
2. The prevalence and clinical correlates of substance use disorders in patients with psychotic disorders from an Upper-Middle-Income Country.
Temmingh HS; Mall S; Howells FM; Sibeko G; Stein DJ
S Afr J Psychiatr; 2020; 26():1473. PubMed ID: 32832129
[TBL] [Abstract][Full Text] [Related]
3. Prevalence, patterns, and correlates of multiple substance use disorders among adult primary care patients.
John WS; Zhu H; Mannelli P; Schwartz RP; Subramaniam GA; Wu LT
Drug Alcohol Depend; 2018 Jun; 187():79-87. PubMed ID: 29635217
[TBL] [Abstract][Full Text] [Related]
4. Persistence/recurrence of and remission from DSM-5 substance use disorders in the United States: Substance-specific and substance-aggregated correlates.
McCabe SE; West BT; Strobbe S; Boyd CJ
J Subst Abuse Treat; 2018 Oct; 93():38-48. PubMed ID: 30126540
[TBL] [Abstract][Full Text] [Related]
5. Prevalence and correlates of alcohol and other substance use disorders in young adulthood: A population-based study.
Latvala A; Tuulio-Henriksson A; Perälä J; Saarni SI; Aalto-Setälä T; Aro H; Korhonen T; Koskinen S; Lönnqvist J; Kaprio J; Suvisaari J
BMC Psychiatry; 2009 Nov; 9():73. PubMed ID: 19925643
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of comorbid substance use in schizophrenia spectrum disorders in community and clinical settings, 1990-2017: Systematic review and meta-analysis.
Hunt GE; Large MM; Cleary M; Lai HMX; Saunders JB
Drug Alcohol Depend; 2018 Oct; 191():234-258. PubMed ID: 30153606
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of DSM-IV and DSM-5 alcohol, cocaine, opioid, and cannabis use disorders in a largely substance dependent sample.
Peer K; Rennert L; Lynch KG; Farrer L; Gelernter J; Kranzler HR
Drug Alcohol Depend; 2013 Jan; 127(1-3):215-9. PubMed ID: 22884164
[TBL] [Abstract][Full Text] [Related]
8. The associations between substance use disorders, schizophrenia-spectrum disorders, and Axis IV psychosocial problems.
Compton MT; Weiss PS; West JC; Kaslow NJ
Soc Psychiatry Psychiatr Epidemiol; 2005 Dec; 40(12):939-46. PubMed ID: 16247563
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of substance use disorders in psychiatric patients: a nationwide Danish population-based study.
Toftdahl NG; Nordentoft M; Hjorthøj C
Soc Psychiatry Psychiatr Epidemiol; 2016 Jan; 51(1):129-40. PubMed ID: 26260950
[TBL] [Abstract][Full Text] [Related]
10. The 3-Year Course of Multiple Substance Use Disorders in the United States: A National Longitudinal Study.
McCabe SE; West BT
J Clin Psychiatry; 2017 May; 78(5):e537-e544. PubMed ID: 28406266
[TBL] [Abstract][Full Text] [Related]
11. Methamphetamine Use and Antipsychotic-related Extrapyramidal Side-effects in Patients with Psychotic Disorders.
Temmingh HS; van den Brink W; Howells F; Sibeko G; Stein DJ
J Dual Diagn; 2020; 16(2):208-217. PubMed ID: 31984872
[No Abstract] [Full Text] [Related]
12. Prevalence of substance use disorders and associations with mindfulness, impulsive personality traits and psychopathological symptoms in a representative sample of adolescents in Germany.
Arnaud N; Wartberg L; Simon-Kutscher K; Thomasius R;
Eur Child Adolesc Psychiatry; 2024 Feb; 33(2):451-465. PubMed ID: 36853515
[TBL] [Abstract][Full Text] [Related]
13. Comorbidity of migraine and psychiatric disorders among substance-dependent inpatients.
McDermott MJ; Tull MT; Gratz KL; Houle TT; Smitherman TA
Headache; 2014 Feb; 54(2):290-302. PubMed ID: 23848988
[TBL] [Abstract][Full Text] [Related]
14. [Cannabis and schizophrenia: demographic and clinical correlates].
Dervaux A; Laqueille X; Bourdel MC; Leborgne MH; Olié JP; Lôo H; Krebs MO
Encephale; 2003; 29(1):11-7. PubMed ID: 12640322
[TBL] [Abstract][Full Text] [Related]
15. Medical Costs of Substance Use Disorders in the US Employer-Sponsored Insurance Population.
Li M; Peterson C; Xu L; Mikosz CA; Luo F
JAMA Netw Open; 2023 Jan; 6(1):e2252378. PubMed ID: 36692881
[TBL] [Abstract][Full Text] [Related]
16. Associations of comorbid substance use disorders with clinical outcomes in schizophrenia using electronic health record data.
Patel R; Chan KMY; Palmer EOC; Valko M; Guruswamy G; Ker S; Batra G; Rentería ME; Kollins SH
Schizophr Res; 2023 Oct; 260():191-197. PubMed ID: 37683509
[TBL] [Abstract][Full Text] [Related]
17. PTSD symptom presentation among people with alcohol and drug use disorders: Comparisons by substance of abuse.
Dworkin ER; Wanklyn S; Stasiewicz PR; Coffey SF
Addict Behav; 2018 Jan; 76():188-194. PubMed ID: 28846939
[TBL] [Abstract][Full Text] [Related]
18. Routine Assessment of Symptoms of Substance Use Disorders in Primary Care: Prevalence and Severity of Reported Symptoms.
Sayre M; Lapham GT; Lee AK; Oliver M; Bobb JF; Caldeiro RM; Bradley KA
J Gen Intern Med; 2020 Apr; 35(4):1111-1119. PubMed ID: 31974903
[TBL] [Abstract][Full Text] [Related]
19. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid substance use disorders.
Beaulieu S; Saury S; Sareen J; Tremblay J; Schütz CG; McIntyre RS; Schaffer A;
Ann Clin Psychiatry; 2012 Feb; 24(1):38-55. PubMed ID: 22303521
[TBL] [Abstract][Full Text] [Related]
20. Occurrence of comorbid substance use disorders among acute psychiatric inpatients at Stikland Hospital in the Western Cape, South Africa.
Weich L; Pienaar W
Afr J Psychiatry (Johannesbg); 2009 Aug; 12(3):213-7. PubMed ID: 19750250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
